Business

Moderna will distribute 34 million doses of its COVID-19 vaccine to countries in difficulty


Moderna announced in a statement on Monday that it will be distributing 34 million doses of its COVID-19 vaccine to developing countries in the fourth quarter of 2021 as part of the global COVAX initiative, which ensures that the vaccine is accessible to countries in difficulty becomes . regardless of income.

The initiative is jointly led by the Coalition for Innovation in Epidemic Preparation, the World Health Organization and Gavi, the Vaccine Alliance. Under the Gavi supply agreement, the Vaccine Alliance has the opportunity to receive 466 million doses in 2022.

Moderna will distribute 34 million doses of its COVID-19 vaccine to countries in difficulty
Moderna will distribute 34 million doses of its COVID-19 vaccine to countries in difficulty

The news comes after the skyrocketing COVID-19 cases and deaths in India and Brazil.

  • To Know More: COVID-19 Vaccine: Which Is The Most Effective

The U.S. Department of State and the Centers for Disease Control and Prevention, also known as the CDC, recently assigned a level 4 travel advisor to India, urging Americans to return home if it is safe enough Department post on Twitter. There have been at least 300,000 cases of Covid-19 daily in India for the past week. Only 9% of the country’s population received the first dose of the vaccine Reuters.

India now has a shortage of medical care and beds for Covid and non-Covid patients, the U.S. Embassy in India recently announced in a health alert.

“We know that many countries have limited resources to get access to COVID-19 vaccines,” said St├ęphane Bancel, CEO of Moderna, in a statement. “We support COVAX’s mission to ensure widespread, affordable and equitable access to COVID-19 vaccines and we continue to work to end this ongoing pandemic with our COVID-19 mRNA vaccine.”

The Moderna two-dose vaccine has been approved for use in Israel, Canada, the European Union, the United Kingdom, Switzerland, Singapore, Qatar, and Taiwan. Other countries are currently examining it for approval. It was approved by the FDA in the United States in December.

Moderna is currently working on the production of a virus-variant-specific booster vaccine that will work against the new variant identified in South Africa.

According to the latest data from John Hopkins University, COVID-19 cases worldwide hit 152.9 million and more than 3.2 million deaths.

Similar Posts